Lipidor Ab Cash Flow Conversion Efficiency

Latest as of June 2024: -0.130x

Lipidor Ab cash flow conversion efficiency. Based on the latest financial reports, Lipidor Ab (LIPI) has a cash flow conversion efficiency ratio of -0.130x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-2.11 Million ≈ $-227.39K USD) by net assets (Skr16.29 Million ≈ $1.75 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Lipidor Ab (2016–2024)

Cash flow conversion efficiency of Lipidor Ab from 2016 to 2024. This chart illustrates how Lipidor Ab's cash flow conversion efficiency has evolved over time, based on yearly financial data. View LIPI live share price for real-time trading data and today's change.

Lipidor Ab Cash Flow Conversion Ratio Explained

Lipidor Ab cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Lipidor Ab Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Lipidor Ab ranked by their cash flow conversion efficiency. Also see Lipidor Ab (LIPI) total market value for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
PERFORMANCE SHIPP.
F:DS2
0.030x
Catenon S.A
MC:COM
0.241x
Control Bionics Ltd
AU:CBL
-0.559x
Smart Concrete Public Company Limited
BK:SMART
0.028x
Bakrie Sumatera Plantations
JK:UNSP
-0.021x
Blossom M&C Co. Ltd
KQ:263920
-0.023x
Wonlim Corp.
KO:005820
-0.016x
Smithson Investment Trust PLC
LSE:SSON
0.000x

Annual Cash Flow Conversion Efficiency for Lipidor Ab (2016–2024)

The table below shows the annual cash flow conversion efficiency of Lipidor Ab from 2016 to 2024. Review Lipidor Ab free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 Skr7.72 Million
≈ $831.01K
Skr-16.08 Million
≈ $-1.73 Million
-2.082x -216.42%
2023-12-31 Skr-9.34 Million
≈ $-1.01 Million
Skr-16.70 Million
≈ $-1.80 Million
1.789x +109.84%
2022-12-31 Skr2.15 Million
≈ $230.94K
Skr-39.00 Million
≈ $-4.20 Million
-18.174x -5811.04%
2021-12-31 Skr43.52 Million
≈ $4.68 Million
Skr-13.38 Million
≈ $-1.44 Million
-0.307x -28.15%
2020-12-31 Skr63.66 Million
≈ $6.85 Million
Skr-15.27 Million
≈ $-1.64 Million
-0.240x +56.67%
2019-12-31 Skr26.83 Million
≈ $2.89 Million
Skr-14.85 Million
≈ $-1.60 Million
-0.554x -185.21%
2018-12-31 Skr14.45 Million
≈ $1.55 Million
Skr-2.81 Million
≈ $-301.86K
-0.194x +81.58%
2017-12-31 Skr3.48 Million
≈ $374.18K
Skr-3.66 Million
≈ $-394.30K
-1.054x +76.02%
2016-12-31 Skr833.68K
≈ $89.72K
Skr-3.66 Million
≈ $-394.30K
-4.395x --

About Lipidor Ab

ST:LIPI Sweden Drug Manufacturers - General
Market Cap
$18.82 Million
Skr174.88 Million SEK
Market Cap Rank
#25143 Global
#497 in Sweden
Share Price
Skr0.22
Change (1 day)
+0.00%
52-Week Range
Skr0.22 - Skr0.22
All Time High
Skr22.60
About

Lipidor AB (publ), a pharmaceutical development company, engages in the development of drugs for the treatment of psoriasis, acne vulgaris, bacterial skin infections, and atopic dermatitis. The company develops AKP-01, which is in Phase III for the treatment of psoriasis; and preclinical stage products, such as AKP-02 for psoriasis, AKP-03 for bacterial skin diseases, and AKP-07 for atopic dermat… Read more